Clinical trial NCT04387201: GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Official title: GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Glucose Intolerance
Overweight and Obesity
Drug Effect
Adiposity
Keywords: GLP-1
prediabetes
brown fat
adipose tissue
IL-6
Lead sponsor: The University of Texas Health Science Center, Houston
Sponsor class: OTHER
Collaborators: name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
First posted: 2020-05-13
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Crossover clinical trial
Primary purpose: BASIC_SCIENCE

Brief summary: This project investigates the anti-obesity mechanisms of glucagon-like peptide-1 (GLP-1) analogs, which are used in the treatment of human obesity and diabetes mellitus. The investigators will test if GLP-1 induces secretion of interleukin-6 (IL-6), a cytokine that may collaborate with GLP-1 analogs to induce the formation of brown fat, which has anti-diabetic properties. The results will guide future obesity and diabetes mellitus therapies.

Detailed description: Incretins, the analogs of glucagon-like peptide-1 (GLP-1), improve glucose control in type 2 diabetes mellitus and counteract obesity through mechanisms that are not completely understood. The investigators' preliminary data show that, in prediabetic human subjects and mice, GLP-1 analog therapy induces an increase in plasma interleukin-6 (IL-6), a cytokine activating signal transducer and activator of transcription 3 (STAT3) signaling, which induces brown (beige) adipocyte differentiation in adipose tissue (AT). The investigators discovered that plasma IL-6 induction occurs through GLP-1 receptor (GLP-1R) stimulation in leukocytes. Interestingly, studies in rodents indicate that GLP-1 / GLP-1R signaling also induces AT beiging. Based on these observations, the investigators hypothesize that incretins induce AT browning in part via transient IL-6 / IL-6 receptor (IL-6R) / STAT3 signaling. The primary objective is to further elucidate the role of IL-6 and GLP-1 signaling in mediating beneficial metabolic effects of incretin therapy. Studies will be paralleled in a human clinical trial, a human cell culture model, and a mouse diet-induced obesity model. GLP-1 analog therapy combined with an IL-6 blocking antibody will be used. Specific Aim 1 is to (A) investigate IL-6 induction / downstream STAT3 signaling and AT browning upon incretin therapy in prediabetic human subjects; and (B) validate mice as a model to study incretin-induced IL-6 signaling as a mediator of AT browning. Specific Aim 2 is to (A) investigate if GLP-1 analog effects on beige adipogenesis depend on IL-6 signaling in human adipocyte progenitors; and (B) investigate if GLP-1 analog effects on beige adipogenesis depend on IL-6 signaling in mice. It is expected that 1) GLP-1 analog signaling via GLP-1R induces IL-6 secretion by leukocytes, and 2) GLP-1 analog therapy induces adipose tissue browning via both direct GLP-1 / GLP-1R signaling and indirect incretin-induced IL-6 / IL-6R / STAT3 signaling. The results of this novel study will give critical insights on the anti-obesity mechanisms of GLP-1 analogs and serve as the basis for developing more targeted therapies for diabetes and obesity. Understanding the anti-diabetic IL-6 effects will also be important for interpreting the results of IL-6 blockade, a therapeutic approach for patients with diabetes and other inflammatory conditions, which may need to be re-considered.

Eligibility criteria: Inclusion criteria:

1. Men and women, ages 18-50 years
2. Diagnosis of Prediabetes - defined as either impaired fasting glucose (fasting glucose of 100-125 mg/dL), impaired glucose tolerance (2-hour postprandial blood glucose of 140-199 mg/dL after 75-gram oral glucose challenge), and/or a hemoglobin A1C ranging from 5.5% to 6.4%.
3. BMI ≤ 35 kg/m2
4. Women of childbearing age must agree to use an acceptable method of pregnancy prevention (barrier methods, abstinence, oral contraception, vaginal rings, long-acting reversible contraceptives, or surgical sterilization) for the duration of the study
5. Patients must have the following laboratory values: Hematocrit ≥ 33 vol%, estimated glomerular filtration rate ≥ 60 mL/min per 1.73 m2, AST (SGOT) \< 2.5 times ULN, ALT (SGPT) \< 2.5 times ULN, alkaline phosphatase \< 2.5 times ULN
6. If patients are receiving antihypertensive medications (other than beta blockers) and/or lipid-lowering medications, they must remain on stable doses for the duration of the study.
7. If patients are receiving NSAIDs or antioxidant vitamins, these must be discontinued one week prior to study initiation and cannot be restarted during the study.
8. If patient takes thyroid medications, these must be dosed to control hypo- or hyperthyroidism.

Exclusion Criteria:

1. History of Type 1 or Type 2 diabetes mellitus
2. Pregnant or breastfeeding women
3. Medications: Beta blockers, corticosteroids, monoamine oxidase inhibitors, diabetes medications (including incretin mimetics and thiazolidinediones), and/or immunosuppressive therapy over the last 2 months.
4. Uncontrolled hypo- or hyperthyroidism
5. Current tobacco use
6. Active malignancy
7. History of clinically significant cardiac, hepatic, or renal disease.
8. History of any serious hypersensitivity reaction to study medications, any other incretin mimetic, any other formulation of supplemental vitamin B12, and/or cobalt
9. Personal or family history of Leber hereditary optic nerve atrophy
10. Prisoners or subjects who are involuntarily incarcerated
11. Compulsorily detention for treatment of either a psychiatric or physical (e.g., infectious disease) illness
12. Prior history of pancreatitis, medullary thyroid cancer, or multiple endocrine neoplasia type 2 (MEN 2)
13. Serum vitamin B12 level above the upper limit of assay detection

Primary outcomes:
measure: Cytokine Interleukin-6 (IL-6) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue)
timeFrame: 6 weeks after start of each intervention
measure: Uncoupling Protein 1 (UCP1) Messenger Ribonucleic Acid (mRNA) Level (From Adipose Tissue)
timeFrame: 6 weeks after start of each intervention
measure: Signal Transducer and Activator of Transcription 3 (STAT3) Band Intensity/Western Blot (From Adipose Tissue)
timeFrame: 6 weeks after start of each intervention
Secondary outcomes:
measure: PR Domain Containing 16 (PRDM16) Messenger Ribonucleic Acid (mRNA) Level ((From Adipose Tissue)
timeFrame: 6 weeks after start of each intervention
measure: Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone) Iron-sulfur protein3 (NDUFS3) (From Adipose Tissue)
timeFrame: 6 weeks after start of each intervention
measure: Beta1-adrenoceptor (ADRB1) (From Adipose Tissue)
timeFrame: 6 weeks after start of each intervention
measure: Beta2-adrenoceptor (ADRB2) (From Adipose Tissue)
timeFrame: 6 weeks after start of each intervention
measure: Beta3-adrenoceptor (ADRB3) (From Adipose Tissue)
timeFrame: 6 weeks after start of each intervention
measure: Nuclear Factor Kappa B (NfKappaB) p65 Band Intensity/Western Blot (From Peripheral Blood Mononuclear Cells)
timeFrame: 6 weeks after start of each intervention
measure: Interleukin-6 (IL-6) mRNA (From Peripheral Blood Mononuclear Cells)
timeFrame: 6 weeks after start of each intervention
measure: IL-6 (From Peripheral Blood Mononuclear Cells)
timeFrame: 6 weeks after start of each intervention
measure: Suppressor of Cytokine Signaling 3 (SOCS3) Band Intensity/Western Blot (From Peripheral Blood Mononuclear Cells)
timeFrame: 6 weeks after start of each intervention
measure: Cytokine IL-6 Level (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Free Fatty Acids Level (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Insulin Level (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Glucose Level (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Tumor Necrosis Factor - Alpha (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Interleukin-4 (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Interleukin-10 (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Interleukin-11 (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Interleukin-13 (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Glucagon-like Peptide-1 (From Plasma)
timeFrame: 6 weeks after start of each intervention
measure: Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
timeFrame: 6 weeks after start of each intervention
measure: Fat Browning Measured as Standard Uptake Value (From Positron Emission Tomography - Computed Tomography (PET-CT) Reading)
timeFrame: 6 weeks after start of each intervention
measure: Oroboros Oxygen Consumption
timeFrame: 6 weeks after start of each intervention
Other outcomes:
Locations:
city: Houston
country: United States
facility: The University of Texas Health Science Center at Houston
state: Texas
Study officials:
affiliation: The University of Texas Health Science Center at Houston, Dept. of Medicine
name: Absalon D Gutierrez, MD
role: PRINCIPAL_INVESTIGATOR
References: